November 5, 2026 | Biofabrication & Medical Innovation
TISSIUM, a medical technology company pioneering programmable biomaterials for tissue reconstruction, has achieved another significant regulatory milestone with the European CE marking of ECLIPSIUM, its light-activated polymer solution for atraumatic hernia repair.
The authorization marks the company’s second major regulatory milestone, following U.S. FDA De Novo authorization of COAPTIUM CONNECT in 2025, a peripheral nerve repair system incorporating a 3D-printed, bioabsorbable polymer implant.
Together, these achievements highlight the growing clinical potential of advanced polymer technologies and additive manufacturing in developing next-generation medical devices.
From 3D-Printed Implants to Light-Activated Surgical Repair
At the center of TISSIUM’s innovation is a proprietary platform of biomorphic programmable polymers designed to interact with biological tissue. The platform supports multiple manufacturing and clinical applications, including high-resolution 3D-printed implants and light-activated tissue fixation.
For COAPTIUM CONNECT, TISSIUM partnered with 3D Systems to develop a specialized additive manufacturing solution capable of producing high-resolution, elastomeric, bioabsorbable implants for peripheral nerve repair. The resulting device combines a 3D-printed implant with a polymer activated during surgery, demonstrating how advanced biofabrication can translate into regulated medical products.
ECLIPSIUM extends the same underlying polymer technology into a different surgical application. Rather than relying on penetrating tacks or sutures, the system uses an applied bioabsorbable polymer activated by light to secure surgical mesh during minimally invasive ventral hernia repair. The approach is designed to reduce tissue trauma while providing surgeons with controlled positioning and on-demand fixation.
Expanding Clinical Applications
The ECLIPSIUM CE marking follows TISSIUM’s European ALPHA clinical study, conducted across centers in Belgium and Spain. The company anticipates an initial European commercial introduction in 2027 while continuing clinical development in the United States through its UNITE randomized controlled trial.
Although the products address distinctly different surgical needs, their development demonstrates how a common biomaterials platform can be adapted across multiple applications, from microscale nerve reconstruction to abdominal wall surgery.
The broader significance extends beyond a single device. TISSIUM’s progress illustrates how the combination of engineered biomaterials, precision 3D printing, and innovative surgical techniques can help bridge the gap between laboratory innovation and clinical adoption.
As advanced manufacturing technologies continue to mature, milestones like these offer encouraging evidence of the role biofabrication can play in developing medical technologies with the potential to improve patient care.
Sources:
Leave a Reply